Progress and Controversies in Gynecologic Oncology

Progress and Controversies in Gynecologic Oncology

2019 prIME Oncology Conference

Not a member of My prIME? Join now for instant access.

Meeting Overview

Join us in Barcelona for the Progress and Controversies in Gynecologic Oncology: 2019 prIME Oncology Conference to get the latest information on gynecologic malignancies from the world’s leading experts. The latest clinical trial data and practical information will be presented in an interactive format, fostering discussions that will impact clinical outcomes for your patients.

We look forward to welcoming you to the conference.

Conference Chairs

Andreas du Bois, MD, PhD

Progress and Controversies in Gynecologic Oncology

Jonathan Ledermann, BSc, MD, FRCP

Progress and Controversies in Gynecologic Oncology

Ignace Vergote, MD, PhD

Progress and Controversies in Gynecologic Oncology

Date and Location

Friday, 25 January 2019
Saturday, 26 January 2019

Crowne Plaza Barcelona – Fira Center
Avda Rius i Taulet, 1-3
Barcelona, Spain



25 – 26 January 2019



Barcelona, Spain

Friday, 25 January 2019

12.30 Welcome and introduction
Ignace Vergote, MD, PhD

Session I
Session Chairs: Ignace Vergote, MD, PhD, and Bradley Monk, MD, FACS, FACOG

12.40 Update on sentinel node biopsy in endometrial cancer: Feasibility, technique, impact, and studies
Jan Persson, MD, PhD
13.05 Case discussion 1: Micrometastasis of 1.5 mm in lymph node (LN) in vulva cancer and frozen section–negative LN
Linn Woelber, MD
13.35 Case discussion 2: One squamous cancer–positive groin LN but no primary tumor (LN CUP groin): What to do, where to stage
Luis Chiva, MD, PhD

Session II
Session Chairs: Nicoletta Colombo, MD, and Ignace Vergote, MD, PhD

14.05 Debate: Is there still a major role for endoscopic radical hysterectomy in cervical cancer?
Pro: Ignace Vergote, MD, PhD
Contra: Nadeem Abu-Rustum, MD, FACOG, FACS
14.45 Management of FIGO stage I cervical cancer: Which surgical approach is used in your center?
Luis Chiva, MD, PhD; Nicoletta Colombo, MD; Jan Persson, MD, PhD; Ignace Vergote, MD, PhD
14.55 Panel discussion
15.05 Break

Session III
Session Chairs: Jonathan Ledermann, BSc, MD, FRCP, and Eric Pujade-Lauraine, MD, PhD

15.25 Is immunotherapy a realistic option for the treatment of cervical and uterine cancers?
Bradley J. Monk, MD, FACS, FACOG
15.50 Case discussion 3: Management of a hypercalcemic small-cell tumor of the ovary
Andrés Poveda, MD
16.20 Case discussion 4: Management of a recurrent granulosa cell tumor
Isabelle Ray-Coquard, MD, PhD
16.50 Changing indications for the use of PARP inhibitors in ovarian cancers: Where is it heading?
Jonathan Ledermann, BSc, MD, FRCP
17.15 Tumor immunology, the biology of ovarian cancer, and treatment implications
An Coosemans, MD, PhD
17.40 The impact of surgical philosophy on outcome
Christina Fotopoulou, MD, PhD
18.05 Panel discussion
18.15 –
IME symposium: Expanding the Role of PARP Inhibitors in Ovarian Cancer: The Ever-Changing Treatment Landscape

Saturday, 26 January 2019

08.30 Welcome and introduction
Nicoletta Colombo, MD

Session IV
Session Chairs: Nicoletta Colombo, MD, and Ignace Vergote, MD, PhD

08.35 Keynote lecture: The new ESGO-ESMO consensus on ovarian cancer
Nicoletta Colombo, MD
09.10 Treatment beyond progression in ovarian cancer
Eric Pujade-Lauraine, MD, PhD
09.35 Case discussion 5: Treatment of recurrent ovarian cancer with a platinum treatment–free interval of 8 months
Antonio González-Martín, MD, PhD
10.05 Case discussion 6: Treatment of recurrent ovarian cancer when platinum is not a good option
Susana Banerjee, MA, MBBS, PhD, FRCP
10.35 Break

Session V
Session Chairs: Andreas du Bois, MD, PhD, and Jonathan Ledermann, BSc, MD, FRCP

11.05 Surgery for recurrent ovarian cancer: Still controversial? (DESKTOP vs GOG-213)
Andreas du Bois, MD, PhD
11.30 Update on gynecologic sarcoma
Jalid Sehouli, MD, PhD
11.55 Debate: The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer
Pro: Willemien van Driel, MD, PhD
Contra: Philipp Harter, MD, PhD
12.45 Break
13.15 Industry-supported satellite symposium
14.30 Break

Session VI
Session Chairs: Nicoletta Colombo, MD, and Andrés Poveda, MD

14.45 How to integrate patient-reported outcomes and quality of life into therapy decisions
Florence Joly-Lobbedez, MD, PhD
15.10 Magnitude of clinical benefit: A provocative concept in gynecologic cancer
Nathan Cherny, MBBS, FRACP, FRCP
15.45 Treatment of complications: Short-term and long-term bowel effects
Christoph Grimm, MD
16.10 Concluding remarks and adjourn
Andreas du Bois, MD, PhD

    Meeting Chairs

  • Andreas du Bois, MD, PhDKliniken Essen-Mitte
    Essen, Germany
  • Jonathan Ledermann, BSc, MD, FRCPUCL Cancer Institute
    London, United Kingdom
  • Ignace Vergote, MD, PhDUniversity Hospitals Leuven
    Leuven, European Union
  • Scientific Committee

  • Nicoletta Colombo, MD, PhDUniversity of Milan–Bicocca
    European Institute of Oncology
    Milan, Italy
  • Bradley J. Monk, MD, FACS, FACOGArizona Oncology (US Oncology Network)
    University of Arizona College of Medicine-Phoenix
    Creighton University School of Medicine at St Joseph's Hospital
    Phoenix, Arizona, United States
  • Andrés Poveda, MDInitia Oncology
    Hospital Quirónsalud
    Valencia, Spain
  • Eric Pujade-Lauraine, MD, PhDCentre Hospitalier Universitaire Hôtel-Dieu
    Paris, France
  • Faculty

  • Nadeem R. Abu-Rustum, MD, FACOG, FACSMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Susana Banerjee, MBBS, MA, PhD, FRCPRoyal Marsden Hospital
    Institute of Cancer Research
    London, United Kingdom
  • Nathan Cherny, MBBS, FRACP, FRCPShaare Zedek Medical Center
    Jerusalem, Israel
  • Luis Chiva, MD, PhDClínica Universidad de Navarra
    Madrid, Spain
  • An Coosemans, MD, PhDUniversity Hospitals Leuven
    Leuven, Belgium
  • Christina Fotopoulou, MD, PhDImperial College London
    London, United Kingdom
  • Antonio González-Martín, MD, PhDClínica Universidad de Navarra
    Madrid, Spain
  • Christoph Grimm, MDMedical University of Vienna
    Vienna, Austria
  • Philipp Harter, MD, PhDKliniken Essen-Mitte
    Essen, Germany
  • Florence Joly-Lobbedez, MD, PhDCentre François Baclesse
    Caen, France
  • Jan Persson, MD, PhDSkåne University Hospital
    Lund, Sweden
  • Isabelle Ray-Coquard, MD, PhDCentre Léon Bérard
    Lyon, France
  • Jalid Sehouli, MD, PhDUniversity Hospital Charité
    Campus Virchow-Klinikum
    Berlin, Germany
  • Willemien van Driel, MD, PhDNetherlands Cancer Institute
    Amsterdam, the Netherlands
  • Linn Woelber, MDUniversity Medical Center Hamburg-Eppendorf
    Hamburg, Germany

The Progress and Controversies in Gynecologic Oncology: 2019 prIME Oncology Conference is intended for gynecologists, oncologists, radiation therapists, surgeons, pathologists, and other practitioners, including allied health professionals, involved in the diagnosis and management of gynecologic malignancies.

After successful completion of this educational activity, participants should be able to:

  • Develop practical approaches for the management of vulvar, cervical, and endometrial cancers
  • Assess standard and emerging therapeutic options for ovarian cancer and describe how the options impact patient outcomes
  • Describe the role of novel agents in the management of gynecologic malignancies
  • Discuss strategies for the management of various rare gynecologic malignancies

Registration Fees


  • Early:  €395
  • Regular: €495
  • Late: €595


  • Early: €225
  • Regular: €300
  • Late: €375


  • Early: €225
  • Regular: €300
  • Late: €375


  • Early: €525
  • Regular: €625
  • Late:  €725

Registration fees include VAT.
*Support documentation of eligibility may be required.

Your registration fee will include:

  • Access to all sessions and exhibition
  • Lunch and coffee breaks
  • Conference documentation

Registration Deadlines
Early registration rate: 22 November 2018 (23.59 CET)
Regular registration rate: 20 December 2018 (23.59 CET)

To Register
You may register online through 23 January 2019 via the “Register Now” button at the top of this page. Registration confirmations will be issued upon successful completion of registration, and reminders will be issued before the meeting. To preregister, registration and payment must be received no later than either 22 November 2018 (early registration rate) or 20 December 2018 (regular registration rate). Please register onsite after 23 January 2019.

Group Registrations
Group registrations will be accepted. For more information, please click “Contact prIME Oncology” at the bottom of this page.

Terms of Payment
All payments must be made in Euros. Payments can be made by credit card.

Registration will only be valid upon prIME Oncology’s receipt of full payment. Outstanding payment must be settled onsite by credit card.

To receive a refund of registration fees, written notice of cancellation must be received. To submit notice of cancellation, please click “Contact prIME Oncology” at the bottom of this page.

The following deadlines and cancellation fee schedule will apply:

  • Before 22 November 2018: €50 administrative charge
  • 22 November 2018 — 19 December 2018: 60% cancellation fee applies on registration fee(s)
  • From 20 December 2018: 100% cancellation fee applies on registration fee(s)
  • Name changes from 20 December 2018: €15 fee is charged per change

Any registration fees remitted will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after 20 December 2018.

prIME Oncology does not accept responsibility for reimbursement of travel, accommodation, or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

We are sorry, but the hotel accommodations at the Crowne Plaza Barcelona – Fira Center are sold out.

Cancellation Fee Hotel Rooms
A cancellation fee may apply in the event that a delegate cancels his/her (registration and) hotel accommodation. A written notice of cancellation must be received.  To submit notice of cancellation, please click “Contact prIME Oncology” at the bottom of this page.

  • Until 15 October 2018: 60% of the total amount due is nonrefundable
  • From 16 October 2018: 100% of the total amount due is nonrefundable
  • From 20 December 2018: A modification fee of €15 applies for all changes

The amount of hotel room fees remitted will be refunded after the Conference. Substitutions are accepted with written notification. In case of no-shows a 100% cancellation fee of the entire stay will apply.

For inquiries related to the Progress and Controversies in Gynecologic Oncology: 2019 prIME Oncology Conference, please click “Contact prIME Oncology” at the bottom of this page.

Schenkkade 50, Suite 16
2595 AR The Hague
the Netherlands

Tel.: + 31 70 30 67 190
Fax: + 31 70 33 18 335

Most EU citizens only need their national identity card or passport to enter Spain. Non-EU citizens require a valid passport to enter Spain, but many countries are exempt from tourist visas. It is essential that you check with the Spanish embassy or consulate in your country before travelling. Without exception, passports must be valid for at least six months after your planned date of departure from Spain.

prIME Oncology will not directly contact embassies and consulates on behalf of applicants. It is the sole responsibility of the delegates to look after their visa requirements.

Note: Passport and visa requirements are liable to change at short notice. Travelers are advised to check their entry requirements with their embassy or consulate.

From Barcelona’s main international airport El Prat you can travel different ways to the Conference venue:

TAXI: Barcelona has 11,500 taxis easily identified by their yellow and black color. It takes 15-20 minutes, depending on traffic.

AEROBUS: This special service is clearly signposted at the stops outside the terminal and it takes you to different parts of the city. The Plaza de España stop is the closest to the hotel, approximately a 5-minute walk from the stop to the hotel.

TRAIN: The station is located to the west of the terminal. Trains go to Sants station. From here you can take either the metro 2 stops to Plaza de España and then a 10-15 minute walk or you can take a taxi.

CAR: Take the Castelldefels motorway (C-31) toward Barcelona to Plaza de España. Turn right on Avenida Maria Cristina and drive until you see the National Palace. Turn left on Avenida Rius i Taulet and carry on straight until Lleida Street. The hotel is right on the corner.

Barcelona has a very good public transport system (TMB), with special ten-trip and one-day, two-day, and three-day tickets available for bus, metro, and local trains. You can call a taxi or flag them down in the streets. In many taxis you can also pay by credit card.

Barcelona has a Mediterranean climate with mild, sunny winters, warm summers, and relatively low rainfall. In January, the average temperature is 13° Celsius (55.4° Fahrenheit).

Barcelona is in the Central European time zone (GMT +1).

Spanish and Catalan are the two main languages spoken in Barcelona. English is also widely spoken and to some extent French and German.

The Spanish currency is the Euro (€).

Value-added tax, or VAT, is otherwise known as IVA (impuesto sobre el valor añadido). The IVA is 10% on accommodation and restaurant prices and is usually, but not always, included in quoted prices. On retail goods the IVA is 21%. IVA-free shopping is available in duty-free shops at all airports for people travelling between EU countries.

Tips are already included in restaurant bills, but it is customary to round up an extra 5% to 10% if you are satisfied with the service. Porters are generally tipped €1 per bag.

This educational activity is supported by:










Several options are available to organizations interested in supporting this conference. For more information, please contact us.

Exhibiting at this conference is possible. For more information, please click “Contact prIME Oncology” at the bottom of this page.

Continuing Education (CE)

Progress and Controversies in Gynecologic Oncology: 2019 prIME Oncology Conference held in Barcelona, Spain, on 25 January 2019 – 26 January 2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 9 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.


This activity is provided by prIME Oncology.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.